Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HST Global signs LOI to acquire treatment facility
According to HST, this acquisition will allow the company to provide alternative healthcare options for those who are suffering from late stage cancer. Ron Howell, president and CEO
According to HST, this acquisition will allow the company to provide alternative healthcare options for those who are suffering from late stage cancer. Ron Howell, president and CEO
On April 17, 2009, CV Therapeutics merged with a wholly-owned subsidiary of Gilead. As a result of the merger, each outstanding share of CV Therapeutics not owned by
The new name reflects a major repositioning of the company to focus development activities on its drug candidate MIS416, which has shown promising activity in preclinical proof-of-principle studies
This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging. The new area will utilize abatement technology, which is used for the elimination
StemCells, a clinical-stage biotechnology company, has granted a non-exclusive license for the company’s recently acquired internal ribosome entry site technology to a major international pharmaceutical company. According to
Under the terms of the agreement, Galapagos will receive an upfront fee of E2.5 million from Merck. In addition, Galapagos is eligible to receive discovery, development and regulatory
The gross proceeds to Hansen Medical, before expenses, from the sale of shares are expected to be $37.99 million. The closing of the offering is expected to take
Norway-based pharmaceutical company Clavis Pharma has initiated the first Phase II study with Intravenous CP-4126 in patients with newly diagnosed, advanced pancreatic cancer. Intravenous CP-4126 is a novel
Ms Mahony joined Lilly more than eight years ago, after more than a decade in sales and marketing roles in the UK and Europe for Amgen, Bristol-Myers Squibb
Galea Life Sciences, a developer of therapeutic functional food products and dietary supplements, has reported that its proprietary Nutraplete therapeutic drink mix, has received approval for Medicaid reimbursement